Brain-derived neurotrophic factor accelerates nitric oxide donor-induced apoptosis of cultured cortical neurons

J Neurochem. 2000 Aug;75(2):494-502. doi: 10.1046/j.1471-4159.2000.0750494.x.

Abstract

Brain-derived neurotrophic factor (BDNF) is known to have important functions in neuronal survival, differentiation, and plasticity. In addition to its role as a survival-promoting factor, BDNF reportedly can enhance neuronal cell death in some cases, for example, the death caused by excitotoxicity or glucose deprivation. The cellular mechanism of the death-enhancing effect of BDNF remains unknown, in contrast to that of its survival-promoting effect. In this work, we found that BDNF markedly accelerated the nitric oxide (NO) donor-induced death of cultured embryonic cortical neurons. BDNF increased the number of cells with nuclear condensation and DNA fragmentation 24 h after treatment with the NO donor, but it did not change the number of those cells 36 h after the treatment. The BDNF-accelerated death of cortical neurons was inhibited by the addition of actinomycin D or cycloheximide. These results suggest that BDNF can accelerate apoptotic cell death elicited by NO donor. TrkB-IgG and K252a blocked the BDNF-induced acceleration of the death, indicating that the death-accelerating effect by BDNF is mediated by TrkB. In addition, the BDNF-accelerated apoptosis was inhibited by the addition of SB202190 and SB203580, specific inhibitors of p38 mitogen-activated protein kinase (MAPK), and U0126, a specific inhibitor of MAPK/ERK kinase 1, indicating that the activation of both p38 MAPK and ERK is involved in the signaling cascade of the BDNF-accelerated, NO donor-induced apoptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects*
  • Brain-Derived Neurotrophic Factor / pharmacology*
  • Butadienes / pharmacology
  • Carbazoles / pharmacology
  • Cell Nucleus / drug effects
  • Cell Survival / drug effects
  • Cells, Cultured
  • Cerebral Cortex / cytology*
  • Cycloheximide / pharmacology
  • DNA Fragmentation / drug effects
  • Dactinomycin / pharmacology
  • Drug Synergism
  • Embryo, Mammalian
  • Enzyme Inhibitors / pharmacology
  • Female
  • Imidazoles / pharmacology
  • Immunoglobulin G / pharmacology
  • Indole Alkaloids
  • Kinetics
  • Male
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Neurons / cytology
  • Neurons / drug effects*
  • Neurons / physiology
  • Nitric Oxide Donors / pharmacology*
  • Nitriles / pharmacology
  • Nitroprusside / pharmacology*
  • Pyridines / pharmacology
  • Rats
  • Rats, Wistar
  • Receptor, trkB / antagonists & inhibitors
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • p38 Mitogen-Activated Protein Kinases

Substances

  • Brain-Derived Neurotrophic Factor
  • Butadienes
  • Carbazoles
  • Enzyme Inhibitors
  • Imidazoles
  • Immunoglobulin G
  • Indole Alkaloids
  • Nitric Oxide Donors
  • Nitriles
  • Pyridines
  • U 0126
  • Nitroprusside
  • Dactinomycin
  • staurosporine aglycone
  • Cycloheximide
  • Receptor, trkB
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • SB 203580
  • 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole